NanoTherapeutics Research Laboratory, Department of Biochemistry and Molecular Biology , University of Miami Miller School of Medicine , Miami , Florida 33136 , United States.
Department of Chemistry , University of Georgia , Athens Georgia 30602 , United States.
ACS Appl Mater Interfaces. 2020 Feb 12;12(6):6852-6862. doi: 10.1021/acsami.9b19036. Epub 2020 Jan 31.
Atherosclerosis is one of the world's most aggressive diseases, claiming over 17.5 million lives per year. This disease is usually caused by high amounts of lipoproteins circulating in the blood stream, which leads to plaque formation. Ultimately, these plaques can undergo thrombosis and lead to major heart damage. A major contributor to these vulnerable plaques is macrophage apoptosis. Development of nanovehicles that carry contrast and therapeutic agents to the mitochondria within these macrophages is attractive for the diagnosis and treatment of atherosclerosis. Here, we report the design and synthesis of a dual-targeted synthetic nanoparticle (NP) to perform the double duty of diagnosis and therapy in atherosclerosis treatment regime. A library of dual-targeted NPs with an encapsulated iron oxide NP, mito-magneto (MM), with a magnetic resonance imaging (MRI) contrast enhancement capability was elucidated. Relaxivity measurements revealed that there is a substantial enhancement in transverse relaxivities upon the encapsulation of MM inside the dual-targeted NPs, highlighting the MRI contrast-enhancing ability of these NPs. Successful in vivo imaging documenting the distribution of MM-encapsulated dual-targeted NPs in the heart and aorta in mice ensured the diagnostic potential. The presence of mannose receptor targeting ligands and the optimization of the NP composition facilitated its ability to perform therapeutic duty by targeting the macrophages at the plaque. These dual-targeted NPs with the encapsulated MM were able to show therapeutic potential and did not trigger any toxic immunogenic response.
动脉粥样硬化是世界上最具侵袭性的疾病之一,每年导致超过 1750 万人死亡。这种疾病通常是由于血液中循环的脂蛋白含量过高引起的,导致斑块形成。最终,这些斑块可能会发生血栓形成,并导致心脏严重受损。导致这些脆弱斑块的一个主要因素是巨噬细胞凋亡。开发能够将对比剂和治疗剂输送到这些巨噬细胞线粒体内部的纳米载体,对于动脉粥样硬化的诊断和治疗具有吸引力。在这里,我们报告了一种双靶向合成纳米颗粒(NP)的设计和合成,以在动脉粥样硬化治疗方案中执行诊断和治疗的双重任务。阐明了具有封装氧化铁 NP(mito-magneto,MM)的双靶向 NP 的库,具有磁共振成像(MRI)对比增强能力。弛豫率测量表明,在双靶向 NP 内封装 MM 后,横向弛豫率有了实质性的增强,突出了这些 NP 的 MRI 对比增强能力。成功的体内成像记录了 MM 封装的双靶向 NP 在小鼠心脏和主动脉中的分布,确保了其诊断潜力。甘露糖受体靶向配体的存在和 NP 组成的优化使其能够通过靶向斑块中的巨噬细胞来执行治疗作用。这些封装了 MM 的双靶向 NP 具有治疗潜力,并且不会引发任何毒性免疫反应。